Associations of antiphospholipid antibodies with splanchnic vein thrombosis: A systematic review with meta-analysis

Medicine (United States)

Volumn 94, Issue 4, 2015, Pages

  Qi, Xingshun ^a,b   De Stefano, Valerio ^c   Su, Chunping ^d   Bai, Ming ^b   Guo, Xiaozhong ^a   Fan, Daiming ^b  

^a GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c CATHOLIC UNIVERSITY   (Italy)

^d FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ANTICOAGULANT; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; PHOSPHOLIPID ANTIBODY; BETA2 GLYCOPROTEIN 1; IMMUNOGLOBULIN; LOW DENSITY LIPOPROTEIN;

ARTICLE; BUDD CHIARI SYNDROME; DATA BASE; DISEASE ASSOCIATION; EMBASE; HUMAN; LIVER CIRRHOSIS; MEDLINE; META ANALYSIS; OBSERVATIONAL STUDY; PORTAL VEIN THROMBOSIS; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SCIENCEDIRECT; SPLANCHNIC VEIN THROMBOSIS; SYSTEMATIC REVIEW; VEIN THROMBOSIS; BLOOD; IMMUNOLOGY; PORTAL VEIN;

ANTIBODIES, ANTIPHOSPHOLIPID; BETA 2-GLYCOPROTEIN I; BUDD-CHIARI SYNDROME; HUMANS; IMMUNOGLOBULINS; LIPOPROTEINS, LDL; LIVER CIRRHOSIS; PORTAL VEIN; VENOUS THROMBOSIS;

EID: 84938076882     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000496     Document Type: Article

References (43)

1. De Stefano V, Martinelli I. Splanchnic vein thrombosis: clinical presentation, risk factors and treatment. Intern Emerg Med. 2010; 5:487-494.
2. Riva N, Donadini MP, Dentali F, et al. Clinical approach to splanchnic vein thrombosis: risk factors and treatment. Thromb Res. 2012; 130 (SUPPL. 1):S1-S3.
3. DeLeve LD, Valla DC, Garcia-Tsao G. Vascular disorders of the liver. Hepatology. 2009; 49:1729-1764.
4. Senzolo M, Riggio O, Primignani M. Vascular disorders of the liver: recommendations from the Italian Association for the Study of the Liver (AISF) ad hoc committee. Dig Liver Dis. 2011; 43:503-514.
5. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). JTH. 2006; 4:295-306.
6. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med. 2002; 346:752-763.
7. Reynaud Q, Lega JC, Mismetti P, et al. Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev. 2014; 13:595-608.
8. Sciascia S, Sanna G, Murru V., et al. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost. 2014; 111:354-364.
9. Galli M, Luciani D, Bertolini G., et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003; 101:1827-1832.
10. Greaves M. Antiphospholipid antibodies and thrombosis. Lancet. 1999; 353:1348-1353.
11. Wahl DG, Guillemin F, de Maistre E, et al. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus. 1998; 7:15-22.
12. Pengo V, Ruffatti A, Legnani C., et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antipho-spholipid antibody profile: a multicenter prospective study. Blood. 2011; 118:4714-4718.
13. Pengo V, Biasiolo A, Pegoraro C., et al. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost. 2005; 93:1147-1152.
14. Pengo V, Ruffatti A, Legnani C., et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. JTH. 2010; 8:237-242.
15. Elefsiniotis IS, Diamantis ID, Dourakis S.P., et al. Anticardiolipin antibodies in chronic hepatitis B and chronic hepatitis D infection, and hepatitis B-related hepatocellular carcinoma. Relationship with portal vein thrombosis. Eur J Gastroenterol Hepatol. 2003; 15:721-726.
16. Gervais A, Czernichow B, Grunebaum L., et al. Serum cardiolipin antibodies in patients with alcoholic cirrhosis. Gastroenterol Clin Biol. 1996; 20:736-742.
17. Egesel T, Buyukasik Y, Dundar S.V., et al. The role of natural anticoagulant deficiencies and factor V Leiden in the development of idiopathic portal vein thrombosis. J Clin Gastroenterol. 2000; 30:66-71.
18. Rebours V, Boudaoud L, Vullierme M.P., et al. Extrahepatic portal venous system thrombosis in recurrent acute and chronic alcoholic pancreatitis is caused by local inflammation and not thrombophilia. Am J Gastroenterol. 2012; 107:1579-1585.
19. Aggarwal R, Ravishankar B, Misra R., et al. Significance of elevated IgG anticardiolipin antibody levels in patients with Budd-Chiari syndrome. Am J Gastroenterol. 1998; 93:954-957.
20. Amitrano L, Ames PR, Guardascione M.A., et al. Antiphospholipid antibodies and antiphospholipid syndrome: role in portal vein thrombosis in patients with and without liver cirrhosis. Clin Appl Thromb Hemost. 2011; 17:367-370.
21. Amitrano L, Anna Guardascione M, Brancaccio V, et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol. 2004; 40:736-741.
22. Amitrano L, Brancaccio V, Guardascione M.A., et al. High prevalence of thrombophilic genotypes in patients with acute mesenteric vein thrombosis. Am J Gastroenterol. 2001; 96:146-149.
23. Amitrano L, Brancaccio V, Guardascione M.A., et al. Portal vein thrombosis after variceal endoscopic sclerotherapy in cirrhotic patients: role of genetic thrombophilia. Endoscopy. 2002; 34:535-538.
24. Amitrano L, Guardascione MA, Brancaccio V, et al. Inherited trombophilic disorders in patients with portal vein thrombosis. J Hepatol. 2000; 32 (suppl 2):133.
25. Egesel T, Unsal I, Bayraktar Y. Antiphospholipid antibodies and lipoprotein (a) as etiologic or contributory factors in patients with idiopathic cavernous transformation of portal vein. Turk J Gastroenterol. 2002; 13:89-93.
26. Gulcan EM, Kutlu T, Erkan T., et al. Anticardiolipin antibodies in children with portal vein thrombosis. Turk Pediatri Arsivi. 2009; 44:124-126.
27. Oksuzoglu G, Bayraktar Y, Arslan S., et al. Portal vein thrombosis in cirrhotics: related with anticardiolipin antibodies? Hepatogastroenterology. 2003; 50:1527-1530.
28. Romero Gomez M, Suarez Garcia E, Lopez Lacomba D, et al. Antiphospholipid antibodies are related to portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol. 2000; 31:237-240.
29. Violi F, Ferro D, Basili S., et al. Increased rate of thrombin generation in hepatitis C virus cirrhotic patients. Relationship to venous thrombosis. J Investig Med. 1995; 43:550-554.
30. Violi F, Ferro D, Basili S., et al. Relation between lupus anticoagulant and splanchnic venous thrombosis in cirrhosis of the liver. BMJ. 1994; 309:239-240.
31. Yachha SK, Aggarwal R, Sharma B.C., et al. Functional protein C and anti-cardiolipin antibody in children with portal vein thrombosis. Indian J Gastroenterol. 2001; 20:47-49.
32. Zocco MA, Di Stasio E, De Cristofaro R, et al. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol. 2009; 51:682-689.
33. Qi X, Ren W, De Stefano V, et al. Associations of coagulation factor V Leiden and prothrombin G20210A mutations with Budd-Chiari syndrome and portal vein thrombosis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014; 12:1801-1812.
34. Qi X, Yang Z, De Stefano V, et al. Methylenetetrahydrofolate reductase C677T gene mutation and hyperhomocysteinemia in Budd-Chiari syndrome and portal vein thrombosis: a systematic review and meta-analysis of observational studies. Hepatol Res. 2014; 44:E480-E498.
35. Qi X, De Stefano V, Wang J, et al. Prevalence of inherited antithrombin, protein C, and protein S deficiencies in portal vein system thrombosis and Budd-Chiari syndrome: a systematic review and meta-analysis of observational studies. J Gastroenterol Hepatol. 2013; 28:432-442.
36. Qi X, Yang Z, Bai M., et al. Meta-analysis: the significance of screening for JAK2V617F mutation in Budd-Chiari syndrome and portal venous system thrombosis. Aliment Pharmacol Ther. 2011; 33:1087-1103.
37. Rolla R, Vay D, Mottaran E., et al. Antiphospholipid antibodies associated with alcoholic liver disease specifically recognise oxidised phospholipids. Gut. 2001; 49:852-859.
38. Biron C, Andreani H, Blanc P., et al. Prevalence of antiphospholipid antibodies in patients with chronic liver disease related to alcohol or hepatitis C virus: correlation with liver injury. J Lab Clin Med. 1998; 131:243-250.
39. Yuste JR, Prieto J. Anticardiolipin antibodies in chronic viral hepatitis. Do they have clinical consequences? Eur J Gastroenterol Hepatol. 2003; 15:717-719.
40. Prieto J, Yuste JR, Beloqui O, et al. Anticardiolipin antibodies in chronic hepatitis C: implication of hepatitis C virus as the cause of the antiphospholipid syndrome. Hepatology. 1996; 23:199-204.
41. Ordi-Ros J, Villarreal J, Monegal F., et al. Anticardiolipin antibodies in patients with chronic hepatitis C virus infection: characterization in relation to antiphospholipid syndrome. Clin Diagn Lab Immunol. 2000; 7:241-244.
42. Mangia A, Margaglione M, Cascavilla I., et al. Anticardiolipin antibodies in patients with liver disease. Am J Gastroenterol. 1999; 94:2983-2987.
43. Harada M, Fujisawa Y, Sakisaka S., et al. High prevalence of anticardiolipin antibodies in hepatitis C virus infection: lack of effects on thrombocytopenia and thrombotic complications. J Gastroenterol. 2000; 35:272-277.